SUBSEQUENT THERAPIES AND TIME TO SECOND PROGRESSION-FREE SURVIVAL EVENTS IN CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA PREVIOUSLY TREATED WITH ZANUBRUTINIB OR BENDAMUSTINE- RITUXIMAB (SIE 2026) - Oct 6, 2026 - Abstract #DP034; Pres time: Sep 21, 2026; 07:00 PM - 08:00 PM; Location: AREA POSTER; "Zanubrutinib demonstrated durable benefit with superior PFS2 despite extensive use of effective subse- quent therapies in the BR arm. Importantly, BCL2i-based sal- vage after zanubrutinib achieved favorable outcomes, sup- porting zanubrutinib as an effective frontline option that pre- serves sensitivity to later therapy."
Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin's Lymphoma • Small Lymphocytic Lymphoma
|
|
A. Tedeschi1; C. Tam2; B. Kahl3; T. Munir4; T. Robak5; J. Brown6; P. Ghia7,8; S. Opat9; P. Walker10; M. Lasica11; I. Flinn12; W. Jurczak13; J. Shen14; M. Lefebure15; J. Hirata14; M. Shadman16,17
|